Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Blood-Brain Barrier (BBB) Delivery Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LDLR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LDLR ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View LDLR Products |
| Gene Delivery | LDLR Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for functional LDL clearance assays. |
View LDLR Products |
| Benchmark Ab | Anti-LDLR Recombinant Antibody Sequence verified positive control. Suitable for flow cytometry and binding assays. |
View LDLR Products |
| Validator | LDLR siRNA Set For knockdown verification in hepatocyte models. |
View LDLR Products |
| Related Target A | PCSK9 Binds LDLR to trigger lysosomal degradation. Crucial for hypercholesterolemia drug screening. |
View PCSK9 Products |
| Related Target B | LRP1 LDL Receptor Related Protein 1. Co-shuttle target for Receptor-Mediated Transcytosis (RMT) across the BBB. |
View LRP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting PCSK9-LDLR pH-dependent binding | HEK293 expressed LDLR ECD-Fc preserving native glycosylation and structural integrity. |
| Measuring functional LDL uptake in vitro | Lentivirus premade particles for stable overexpression of full-length LDLR in HepG2/CHO cells. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live LDLR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the LDLR pathway represents a cornerstone of cardiovascular medicine, primarily governed by the PCSK9-LDLR degradation axis. Beyond lipid management, LDLR is emerging as a premier target for Receptor-Mediated Transcytosis (RMT) to deliver biotherapeutics across the Blood-Brain Barrier (BBB). The next wave of R&D focuses on optimizing low-affinity LDLR-binding shuttles to maximize brain penetration while avoiding systemic clearance, alongside small molecule PCSK9-LDLR protein-protein interaction (PPI) inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (anti-PCSK9) | Amgen, Regeneron, Sanofi | Hypercholesterolemia, ASCVD | PCSK9-LDLR binding inhibition assay (Need high-purity LDLR ECD-Fc) |
| Peptide-Drug Conjugates (BBB Shuttles) | Angiochem, Denali Therapeutics | Lysosomal Storage Diseases, Glioblastoma | pH-dependent dissociation assay (Need sequence-verified LDLR ECD) |
| Gene Therapy / mRNA | Verve Therapeutics, Intellia | Homozygous Familial Hypercholesterolemia (HoFH) | Functional uptake rescue assays (Need LDLR Lentivirus for stable cell lines) |